Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free BCAX Stock Alerts

Bicara Therapeutics (BCAX) Financials

Bicara Therapeutics logo
$22.00 +0.02 (+0.11%)
As of 01:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Bicara Therapeutics

Annual Income Statements for Bicara Therapeutics

This table shows Bicara Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -52 -68 -138
Consolidated Net Income / (Loss)		 -52 -68 -138
Net Income / (Loss) Continuing Operations		 -52 -68 -138
Total Pre-Tax Income 		-52 -68 -138
Total Operating Income		 -40 -82 -156
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 40 82 156
Selling, General & Admin Expense		 9.27 19 31
Research & Development Expense		 31 64 125
Total Other Income / (Expense), net		 -12 15 18
Interest & Investment Income		 1.31 15 18
Income Tax Expense		 0.01 0.19 0.22
Basic Earnings per Share		 ($89.61) ($4.05) ($2.52)
Weighted Average Basic Shares Outstanding		 580.11K 16.81M 54.68M
Diluted Earnings per Share		 ($89.61) ($4.05) ($2.52)
Weighted Average Diluted Shares Outstanding		 580.11K 16.81M 54.68M
Weighted Average Basic & Diluted Shares Outstanding		 - 54.52M 65.47M

Quarterly Income Statements for Bicara Therapeutics

This table shows Bicara Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -13 -17 -17 -21 -37 -27 -36 -37 -56
Consolidated Net Income / (Loss)		 -23 -13 -17 -17 -21 -37 -27 -36 -37 -56
Net Income / (Loss) Continuing Operations		 -23 -13 -17 -17 -21 -37 -27 -36 -37 -56
Total Pre-Tax Income 		-23 -13 -17 -17 -21 -37 -27 -36 -37 -56
Total Operating Income		 -9.53 -15 -20 -21 -27 -42 -32 -41 -41 -60
Total Gross Profit		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.49 15 20 21 27 42 32 41 41 60
Selling, General & Admin Expense		 2.59 3.34 3.91 4.76 6.76 7.46 7.22 7.70 8.13 13
Research & Development Expense		 6.90 12 16 16 20 34 25 33 33 48
Total Other Income / (Expense), net		 -13 2.87 2.70 3.15 5.87 5.01 4.68 4.39 3.79 4.08
Interest & Investment Income		 0.01 2.87 2.70 3.15 5.87 5.01 4.68 4.39 3.79 4.08
Income Tax Expense		 0.00 0.00 0.00 0.00 0.19 0.07 0.05 0.04 0.05 0.05
Basic Earnings per Share		 ($38.23) ($18.94) ($19.01) ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67) ($0.93)
Weighted Average Basic Shares Outstanding		 597.59K 660.29K 896.74K 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M 60.72M
Diluted Earnings per Share		 ($38.23) ($18.94) ($19.01) ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67) ($0.93)
Weighted Average Diluted Shares Outstanding		 597.59K 660.29K 896.74K 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M 60.72M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 54.42M 54.52M 54.54M 54.56M 54.78M 65.47M 65.70M

Annual Cash Flow Statements for Bicara Therapeutics

This table details how cash moves in and out of Bicara Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 226 259 -393
Net Cash From Operating Activities		 -46 -75 -107
Net Cash From Continuing Operating Activities		 -46 -75 -107
Net Income / (Loss) Continuing Operations		 -52 -68 -138
Consolidated Net Income / (Loss)		 -52 -68 -138
Depreciation Expense		 0.02 0.06 0.11
Amortization Expense		 - 0.00 0.30
Non-Cash Adjustments To Reconcile Net Income		 16 7.40 15
Changes in Operating Assets and Liabilities, net		 -9.58 -14 16
Net Cash From Investing Activities		 -0.59 -0.01 -318
Net Cash From Continuing Investing Activities		 -0.59 -0.01 -318
Purchase of Property, Plant & Equipment		 -0.59 -0.07 -0.28
Purchase of Investments		 - 0.00 -318
Sale of Property, Plant & Equipment		 0.00 0.06 0.00
Net Cash From Financing Activities		 272 334 32
Net Cash From Continuing Financing Activities		 272 334 32
Issuance of Common Equity		 0.00 332 29
Other Financing Activities, net		 0.15 1.60 2.76

Quarterly Cash Flow Statements for Bicara Therapeutics

This table details how cash moves in and out of Bicara Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 186 -14 -12 317 -31 -28 -25 -265 -75 227
Net Cash From Operating Activities		 -8.04 -15 -13 -17 -30 -28 -26 -29 -24 -38
Net Cash From Continuing Operating Activities		 -8.04 -15 -13 -17 -30 -28 -26 -29 -24 -38
Net Income / (Loss) Continuing Operations		 -12 -13 -17 -17 -21 -37 -27 -36 -37 -56
Consolidated Net Income / (Loss)		 -12 -13 -17 -17 -21 -37 -27 -36 -37 -56
Depreciation Expense		 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.04 0.04
Amortization Expense		 - 0.07 0.07 0.07 - 0.00 0.21 -0.32 0.27 0.34
Non-Cash Adjustments To Reconcile Net Income		 1.41 1.15 0.90 1.96 3.20 3.44 3.17 4.54 3.81 5.86
Changes in Operating Assets and Liabilities, net		 2.98 -3.30 3.16 -1.79 -12 5.28 -1.61 2.84 9.37 12
Net Cash From Investing Activities		 -0.44 0.06 -0.02 -0.01 -0.04 0.00 - -236 -82 101
Net Cash From Continuing Investing Activities		 -0.44 0.06 -0.02 -0.01 -0.04 0.00 - -236 -82 101
Purchase of Property, Plant & Equipment		 -0.44 -0.00 -0.02 -0.01 -0.04 0.00 - -0.04 -0.24 -0.06
Sale and/or Maturity of Investments		 - - - - - 0.00 - - - 101
Net Cash From Financing Activities		 195 0.14 0.73 334 -0.98 0.46 0.14 0.44 31 163
Net Cash From Continuing Financing Activities		 195 0.14 0.73 334 -0.98 0.46 0.14 0.44 31 163
Issuance of Common Equity		 - - - - -1.05 0.00 - - 29 162
Other Financing Activities, net		 - 0.14 1.33 0.06 0.08 0.46 0.14 0.44 1.73 1.58
Cash Income Taxes Paid		 - 0.00 - - - 0.07 0.05 0.17 - 0.00

Annual Balance Sheets for Bicara Therapeutics

This table presents Bicara Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 234 510 431
Total Current Assets		 231 503 422
Cash & Equivalents		 230 490 97
Short-Term Investments		 - 0.00 318
Prepaid Expenses		 0.63 13 7.25
Plant, Property, & Equipment, net		 0.20 0.16 0.33
Total Noncurrent Assets		 2.71 7.31 8.61
Other Noncurrent Operating Assets		 2.71 7.31 8.61
Total Liabilities & Shareholders' Equity		 234 510 431
Total Liabilities		 15 18 30
Total Current Liabilities		 15 18 29
Accounts Payable		 3.19 4.51 7.79
Accrued Expenses		 12 13 20
Other Current Liabilities		 0.29 0.61 1.12
Total Noncurrent Liabilities		 0.39 0.13 0.59
Other Noncurrent Operating Liabilities		 0.39 0.13 0.59
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -149 492 401
Total Preferred & Common Equity		 -149 492 401
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -149 492 401
Common Stock		 4.25 713 760
Retained Earnings		 -153 -221 -359
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.24

Quarterly Balance Sheets for Bicara Therapeutics

This table presents Bicara Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 524 478 454 425 554
Total Current Assets		 522 471 444 297 545
Cash & Equivalents		 521 462 437 172 323
Short-Term Investments		 - - - 118 216
Prepaid Expenses		 0.76 8.69 7.79 7.21 5.16
Plant, Property, & Equipment, net		 0.13 0.14 0.12 0.14 0.35
Total Noncurrent Assets		 2.53 7.19 9.08 127 8.34
Other Noncurrent Operating Assets		 2.53 7.19 9.08 9.76 8.34
Total Liabilities & Shareholders' Equity		 524 478 454 425 554
Total Liabilities		 15 19 18 22 40
Total Current Liabilities		 14 19 17 21 39
Accounts Payable		 1.96 2.74 2.91 3.66 7.44
Accrued Expenses		 12 16 13 16 31
Other Current Liabilities		 0.31 0.59 1.07 1.10 1.14
Total Noncurrent Liabilities		 0.14 0.00 1.16 0.88 0.30
Other Noncurrent Operating Liabilities		 0.14 0.00 1.16 0.88 0.30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 510 459 435 403 514
Total Preferred & Common Equity		 510 459 435 403 514
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 510 459 435 403 514
Common Stock		 710 717 720 724 929
Retained Earnings		 -200 -258 -285 -322 -415
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.14 -0.24

Annual Metrics And Ratios for Bicara Therapeutics

This table displays calculated financial ratios and metrics derived from Bicara Therapeutics' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - 54,781,950.00
DEI Adjusted Shares Outstanding		 - - 54,781,950.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -2.52
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -28 -58 -109
Return On Investment Capital (ROIC_SIMPLE)		 18.77% -11.73% -27.13%
Earnings before Interest and Taxes (EBIT)		 -53 -82 -156
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -82 -155
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -72 -93
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 -12 2.16 -13
Increase / (Decrease) in Invested Capital		 0.00 14 -16
Book Value per Share		 ($256.45) $9.04 $7.33
Tangible Book Value per Share		 ($256.45) $9.04 $7.33
Total Capital		 219 492 401
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -230 -490 -415
Capital Expenditures (CapEx)		 0.59 0.01 0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -5.17 -22
Debt-free Net Working Capital (DFNWC)		 216 485 393
Net Working Capital (NWC)		 216 485 393
Net Nonoperating Expense (NNE)		 24 10 29
Net Nonoperating Obligations (NNO)		 -230 -490 -415
Total Depreciation and Amortization (D&A)		 0.02 0.06 0.41
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.05) ($2.52)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 16.81M 54.68M
Adjusted Diluted Earnings per Share		 $0.00 ($4.05) ($2.52)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 16.81M 54.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.52M 65.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -58 -109
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Bicara Therapeutics

This table displays calculated financial ratios and metrics derived from Bicara Therapeutics' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - 54,415,619.00 - - - 54,781,950.00 65,467,187.00
DEI Adjusted Shares Outstanding		 - - - - 54,415,619.00 - - - 54,781,950.00 65,467,187.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - -0.39 - - - -0.68 -0.86
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 9.76% - -172.17% -61.60% -99.41% - -43.31%
EBIT Growth		 0.00% 0.00% 0.00% 9.76% - -171.81% -62.12% -97.19% - -44.16%
NOPAT Growth		 0.00% 0.00% 0.00% -116.45% - -171.81% -62.12% -97.19% - -44.16%
Net Income Growth		 0.00% 0.00% 0.00% 23.48% - -194.58% -60.64% -107.83% - -52.56%
EPS Growth		 0.00% 0.00% 0.00% 95.81% - 96.41% 97.37% 58.13% - -36.76%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% - -92.68% -98.28% -69.81% - -33.45%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% -977.43% - 25.48%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 57.12% - -729.96%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -28.60% 0.00% - 0.00% 23.64% -28.88% - -46.68%
EBIT Q/Q Growth		 0.00% 0.00% -28.46% 0.00% - 0.00% 23.38% -27.04% - -46.50%
NOPAT Q/Q Growth		 0.00% 0.00% -28.46% 0.00% - 0.00% 23.38% -27.04% - -46.50%
Net Income Q/Q Growth		 0.00% 0.00% -36.30% 0.00% - 0.00% 25.67% -32.65% - -50.35%
EPS Q/Q Growth		 0.00% 0.00% -0.37% 0.00% - 0.00% 26.47% -34.00% - -38.81%
Operating Cash Flow Q/Q Growth		 0.00% -81.52% 11.51% 0.00% - 6.41% 8.94% -14.28% - -57.03%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 19.66% -66.04% - -46.79%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 54.63% -240.71% - -93.24%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.01% 100.00% 100.00% - 100.20% 100.19% 100.11% - 100.09%
Interest Burden Percent		 99.94% 81.35% 86.32% 84.74% - 88.00% 85.38% 89.22% - 93.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% - -20.12% -23.59% -26.64% - -32.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% - -20.12% -23.59% -26.64% - -32.34%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% - -20.12% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.67 -11 -14 -14 -19 -29 -22 -28 -29 -42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -1.17% - -3.29% -2.28% -1.69% - -2.80%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -3.79% -6.37% -5.15% -7.07% -7.17% -8.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -15 -20 -21 -27 -42 -32 -41 -41 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -15 -20 -21 -27 -42 -32 -41 -41 -60
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.54 - 1.55 1.16 2.14 - 2.35
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.54 - 1.55 1.16 2.14 - 2.35
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Financial Leverage		 0.00 0.00 0.00 -1.02 - -1.01 -1.00 -1.02 - -1.03
Leverage Ratio		 0.00 0.00 0.00 1.03 - 1.04 1.04 1.04 - 1.06
Compound Leverage Factor		 0.00 0.00 0.00 0.87 - 0.92 0.89 0.93 - 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% - 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 - 22.36 16.55 23.00 - 17.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 36.01 - 24.62 25.80 14.14 - 13.85
Quick Ratio		 0.00 0.00 0.00 35.96 - 24.17 25.34 13.80 - 13.72
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -3.24 0.00 -26 -21 -35 -13 -19
Operating Cash Flow to CapEx		 0.00% 0.00% -67,936.84% 0.00% - 0.00% 0.00% -69,638.10% - -62,513.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -11 2.16 -3.11 -1.41 -4.80 -13 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -11 0.00 -3.11 -1.41 6.40 -16 -23
Enterprise Value (EV)		 0.00 0.00 0.00 -243 - 248 70 454 - 668
Market Capitalization		 315 315 315 278 - 710 507 862 - 1,208
Book Value per Share		 $0.00 $0.00 $0.00 $46.74 $9.04 $8.42 $7.98 $7.38 $7.33 $7.85
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $46.74 $9.04 $8.42 $7.98 $7.38 $7.33 $7.85
Total Capital		 0.00 0.00 0.00 510 492 459 435 403 401 514
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -521 -490 -462 -437 -408 -415 -540
Capital Expenditures (CapEx)		 0.00 -0.06 0.02 0.00 0.04 0.00 0.00 0.04 0.24 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -14 -5.17 -10 -9.44 -14 -22 -34
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 507 485 452 427 276 393 506
Net Working Capital (NWC)		 0.00 0.00 0.00 507 485 452 427 276 393 506
Net Nonoperating Expense (NNE)		 16 1.75 3.22 3.04 2.31 7.59 4.98 7.86 8.60 14
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -521 -490 -462 -437 -408 -415 -540
Total Depreciation and Amortization (D&A)		 0.00 0.08 0.08 0.00 -0.18 0.16 0.23 -0.29 0.31 0.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67) ($0.93)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M 60.72M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.60) $35.50 ($0.68) ($0.50) ($0.67) ($0.67) ($0.93)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 10.90M 16.81M 54.46M 54.54M 54.56M 54.68M 60.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 54.42M 54.52M 54.54M 54.56M 54.78M 65.47M 65.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.67 -11 -14 -14 -19 -29 -22 -28 -29 -42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are key trends from Bicara Therapeutics (BCAX) across quarterly reports over the last four years, focusing on cash flow, profitability, and the balance sheet. Items are shown with positives first, then neutral, then negatives.

  • Q4 2025: Issuance of Common Equity added about $29.5 million in cash, and net financing cash flow was roughly $31.2 million, boosting near-term liquidity.
  • Historical funding activity has provided runway to support R&D (for example, Q4 2023 saw a significant cash inflow from issuance of Preferred Equity of about $194.7 million).
  • Balance sheet shows a strong equity cushion with relatively low liabilities: in 2025 Q3, Total Liabilities were about $21.9 million versus Total Assets around $424.7 million, indicating modest leverage.
  • A sizable cash cushion has existed in prior periods (e.g., Cash & Equivalents around $520.8 million in 2024 Q3 and about $462.1 million in 2025 Q1), providing liquidity headroom for clinical development.
  • Total revenue has been minimal or zero in most quarters, consistent with Bicara’s ongoing pre-revenue development stage.
  • Weighted-average shares outstanding are in the mid-50 million range (roughly 54.5–54.6 million in 2025), indicating some dilution risk from equity financing while keeping per-share losses in check with higher share counts.
  • R&D and SG&A expenses dominate operating costs, signaling continued heavy investment in clinical programs rather than near-term profitability.
  • Net cash from continuing operating activities is negative in every reported 2025 quarter, reflecting ongoing cash burn from operations.
  • Investing activities show substantial cash outflows in mid-2025 (approximately $236.1 million in Q3 2025 and about $82.1 million in Q2 2025), indicating significant capital deployment alongside ongoing development efforts.
  • Net income attributable to common shareholders was negative in 2025 Q4, around $-37.386 million, consistent with ongoing losses and no material revenue.
05/27/26 01:13 PM ETAI Generated. May Contain Errors.

Bicara Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bicara Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bicara Therapeutics' net income appears to be on an upward trend, with a most recent value of -$137.95 million in 2025, rising from -$51.99 million in 2023. The previous period was -$68.00 million in 2024. See Bicara Therapeutics' forecast for analyst expectations on what's next for the company.

Bicara Therapeutics' total operating income in 2025 was -$155.60 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $155.60 million

Over the last 2 years, Bicara Therapeutics' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

Bicara Therapeutics' total liabilities were at $29.54 million at the end of 2025, a 63.0% increase from 2024, and a 90.9% increase since 2023.

In the past 2 years, Bicara Therapeutics' cash and equivalents has ranged from $96.69 million in 2025 to $489.71 million in 2024, and is currently $96.69 million as of their latest financial filing in 2025.

Over the last 2 years, Bicara Therapeutics' book value per share changed from -256.45 in 2023 to 7.33 in 2025, a change of -102.9%.


Related Companies

Financial statements for NASDAQ:BCAX last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel